For years, the clinical trial industry has been sold an appealing idea: participant adherence is largely a problem that can ...
In this conversation between Rebecca Johnson, PhD, ACT EAB member and clinical research recruitment and inclusion executive ...
In today's ACT Brief, we examine leadership instability and regulatory uncertainty during Makary's FDA tenure, how lived ...
Signant’s acquisition of Ametris consolidates patient-reported outcomes and continuous wearable sensing into one workflow, reducing multi-vendor operational overhead and dataset reconciliation ...
FDA Commissioner Marty Makary, MD, MPH, resigned Tuesday, according to The Associated Press, just 13 months after being ...
In today's ACT Brief, we examine cost models for imaging infrastructure in clinical trials, how community relationships ...
A multi-stakeholder tabletop exercise evaluated SSDC integration into pragmatic trials, emphasizing fit-for-purpose safety ...
A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
Week-24 TRuE-AD4 outcomes with ruxolitinib 1.5% cream showed 84.3% EASI75 and 70.6% IGA Treatment Success among completers ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
Guselkumab (Tremfya) showed higher 24-week fistula remission than placebo in adults with perianal fistulizing Crohn disease.
Lastly, a broader view of clinical outcomes and operational insights is a cornerstone to product value translation. Gathering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results